-
1 Comment
Plus Therapeutics, Inc is currently in a long term downtrend where the price is trading 2.8% below its 200 day moving average.
From a valuation standpoint, the stock is 97.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 34.3.
Plus Therapeutics, Inc's total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has dropped by 505.8% to $-4M since the same quarter in the previous year.
Finally, its free cash flow fell by 435.7% to $-3M since the same quarter in the previous year.
Based on the above factors, Plus Therapeutics, Inc gets an overall score of 1/5.
Sector | Healthcare |
---|---|
Exchange | NASDAQ |
CurrencyCode | USD |
ISIN | US72941H4002 |
Industry | Biotechnology |
Market Cap | 12M |
---|---|
PE Ratio | None |
Target Price | 9.8333 |
Beta | 0.88 |
Dividend Yield | None |
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic drug candidate is REYOBIQ, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for PSTV using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025